OAN Staff Brooke Mallory
5:40 PM – Monday, August 31, 2026
In a major policy milestone for healthcare reform, President Donald Trump announced nine new agreements with pharmaceutical manufacturers aimed at slashing prescription drug costs for Americans.
Under these voluntary deals, manufacturers agree to align U.S. drug pricing with the lowest prices paid by other developed countries, a framework known as the most-favored-nation (MFN) price model. The latest expansion brings the total roster of pharmaceutical companies participating in MFN pricing to 26, collectively representing roughly 89% of…




